Expressions and clinical significances of ER，PR，HER-2 and Ki67 in young women with breast carcinoma

Abstract:

Objective：To discuss the expressions of estrogen receptor（ER），progesterone receptor（PR），human epidemic receptor-2 （HER-2） and Ki67 in young women（≤35 years old） with breast carcinoma in Xinjiang and to explore the relationship between the expressions and the clinical pathological characteristics. Methods：The expressions of ER，PR，HER-2 and Ki67 in 70 young women with breast cancer were detected by immunohistochemical method and their relationship with the clinical pathological characteristics was analyzed. Results：The positive rate of ER，PR，HER-2 and Ki67 in 70 young women with breast carcinoma of were 74.3%（52/70），71.40%（50/70），32.90%（23/70） and 97.1%（68/70）. Statistical differences in the expressions of HER-2 were observed in groups with different tumor sizes and groups with or without lymph node metastasis（P<0.05）；statistical differences in the expressions of Ki67 were observed in groups with different nationalities and histological gradings and groups with or without lymph node metasta－sis（P<0.05）. No statistical difference in the expression of ER and PR was observed in groups with different nationalities and histologi－cal gradings，groups with different tumor sizes and groups with or without lymph node metastasis（P >0.05）；no statistical difference in the expression of HER-2 was observed in groups with different nationalities and histological gradings（P >0.05）；no statistical difference in the expression of Ki67 was observed in groups with different tumor sizes（P >0.05）. Conclusions：（1）The expressions of ER and PR in young women with breast carcinoma are high，but the expressions are not related with clinical pathological features.（2）The expres－sions of HER-2 and Ki67 are related with malignancy grading and metastasis. （3）The expressions of Ki67 are high and show vari－ances in groups with different nationalities. （4）Combined detection of ER，PR，HER-2 and Ki67 can be used as criterion of biologi－cal behavior and prognosis in young women with breast carcinoma.